Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …

Applications of viral vectors have found an encouraging new beginning in gene therapy in
recent years. Significant improvements in vector engineering, delivery, and safety have …

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

Effective immunotherapy of stromal-rich tumors requires simultaneous targeting of cancer
cells and immunosuppressive elements of the microenvironment. Here, we modified the …

Immuno-oncology (IO) has been an active area of oncology research. Following US FDA
approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA …

Oncolytic virus therapy is a cancer treatment modality that has the potential to improve
outcomes for patients with currently incurable malignancies. Although intravascular delivery …

Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …

Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing
progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group …

Highlights•Membrane cofactor protein (MCP; CD46) protects host cells from complement
attack.•Rare variants leading to haploinsufficiency predispose to renal disease.•Subversion …

Adenovirus is a highly evolutionary successful pathogen, as it is widely prevalent across the
animal kingdom, infecting hosts ranging from lizards and frogs to dolphins, birds, and …